search
Back to results

Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter (FLO THRU)

Primary Purpose

Peripheral Arterial Disease, Superficial Femoral Artery Stenosis

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Fractional Flow Reserve (FFR)
High Definition Intravascular Ultrasound (HD-IVUS)
Sponsored by
Acist Medical Systems
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Peripheral Arterial Disease

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-79 at the time of planned SFA intervention
  • SFA lesion requires intervention (according to ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention, ABI, imaging, and/or clinical symptoms)
  • Index SFA lesion is ≤150 mm
  • Rutherford Classification of Peripheral Artery Disease (PAD) is Class 2, 3, 4, or 5
  • Minimum two vessel run-off without a hemodynamically significant lesion below the treatment lesion (in at least one vessel to the foot) in the opinion of the treating physician

Exclusion Criteria:

  • Study lesion is a Chronic Total Occlusion (CTO)
  • Clinically significant (in the opinion of the treating physician) inflow disease of the aorta, common iliac, external iliac, or common femoral artery
  • Presence of an additional hemodynamically significant stenosis within the SFA in the opinion of the treating physician
  • Active cancer (any type)
  • Life expectancy less than 1 year
  • Pregnancy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    Main study arm

    Sub-study

    Arm Description

    All subjects will have their SFA lesion assessed with FFR measurement.

    Last 50 enrolled subjects will have HD-IVUS in addition to FFR.

    Outcomes

    Primary Outcome Measures

    Post-PVI FFR
    Explore the correlation of post-PVI FFR values with other established clinical measures (i.e. 6MWT, ABI, VQ-6, WIQ, and arterial duplex US)

    Secondary Outcome Measures

    Full Information

    First Posted
    October 4, 2021
    Last Updated
    October 18, 2022
    Sponsor
    Acist Medical Systems
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05079906
    Brief Title
    Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
    Acronym
    FLO THRU
    Official Title
    Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2022
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Withdrawn due to timing
    Study Start Date
    May 2022 (Anticipated)
    Primary Completion Date
    June 2024 (Anticipated)
    Study Completion Date
    June 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Acist Medical Systems

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study is intended to help establish standard procedures for use of FFR in the peripheral arterial system and to evaluate the correlation of post-procedural FFR values and clinical outcomes in Superficial Femoral artery (SFA) interventions in subjects ages 18 to 79 with PAD.
    Detailed Description
    The ACIST Navvus Rapid Exchange FFR MicroCatheter is a rapid exchange catheter with a pressure sensor located at the distal tip that allows the operator to use their preferred standard 0.014-inch coronary guidewire for peripheral vascular intervention (PVI), eliminating the need for a wire exchange. The fractional flow reserve (FFR) measurements obtained with Navvus represent the degree of stenosis in an artery via comparison of the distal lesion value to the proximal lesion value. While FFR has evolved as the gold standard for identifying coronary stenoses that may cause myocardial ischemia, it remains underutilized in the diagnosis and treatment of peripheral lesions. FFR cutoff values which could guide PVI decisions are yet to be defined and accepted. Routine use of FFR in patients with peripheral artery disease (PAD) may play an important role in determining the appropriateness of interventions in the peripheral vasculature by introducing a more objective assessment. Shishehbor and Agarwal further highlighted the potential economic benefit of FFR use in peripheral vessels by stating "The Affordable Care Act and higher emphasis on quality rather than quantity should support the use of [IVUS or FFR] to make peripheral interventions more accurate, safer, and better". This study is intended to help establish standard procedures for use of FFR in the peripheral arterial system and to evaluate the correlation of post-procedural FFR values and clinical outcomes in Superficial Femoral artery (SFA) interventions in subjects ages 18 to 79 with PAD (Rutherford Classification 2, 3, 4, or 5). FFR measurements will be collected using the Navvus catheter pre- and post-PVI. A subset of study subjects will also have post-intervention IVUS imaging performed with the Kodama catheter.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Peripheral Arterial Disease, Superficial Femoral Artery Stenosis

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Main study arm
    Arm Type
    Other
    Arm Description
    All subjects will have their SFA lesion assessed with FFR measurement.
    Arm Title
    Sub-study
    Arm Type
    Other
    Arm Description
    Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
    Intervention Type
    Device
    Intervention Name(s)
    Fractional Flow Reserve (FFR)
    Intervention Description
    Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
    Intervention Type
    Device
    Intervention Name(s)
    High Definition Intravascular Ultrasound (HD-IVUS)
    Intervention Description
    High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
    Primary Outcome Measure Information:
    Title
    Post-PVI FFR
    Description
    Explore the correlation of post-PVI FFR values with other established clinical measures (i.e. 6MWT, ABI, VQ-6, WIQ, and arterial duplex US)
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    79 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 18-79 at the time of planned SFA intervention SFA lesion requires intervention (according to ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention, ABI, imaging, and/or clinical symptoms) Index SFA lesion is ≤150 mm Rutherford Classification of Peripheral Artery Disease (PAD) is Class 2, 3, 4, or 5 Minimum two vessel run-off without a hemodynamically significant lesion below the treatment lesion (in at least one vessel to the foot) in the opinion of the treating physician Exclusion Criteria: Study lesion is a Chronic Total Occlusion (CTO) Clinically significant (in the opinion of the treating physician) inflow disease of the aorta, common iliac, external iliac, or common femoral artery Presence of an additional hemodynamically significant stenosis within the SFA in the opinion of the treating physician Active cancer (any type) Life expectancy less than 1 year Pregnancy

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter

    We'll reach out to this number within 24 hrs